Payment overview · 2025
General Payments
$817.91
16 reported records · 10 companies
Healthcare provider profile · identity verified
Michelle M Zhang, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · RENTON, WA · NPI 1366553513
Verified facts
What the public records show
CMS Open Payments records show Michelle M Zhang, MD received $817.91 in general payments during 2025 across 16 reported records.
ABBVIE INC. accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Imbruvica, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Imbruvica by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERZENIO as an associated drug or biological on 9278 records involving 4763 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Verzenio by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $187.59 | 22.9% | 4 | 2025 |
| Genentech, Inc. | Unresolved — no canonical attribution shown | $132.13 | 16.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $107.42 | 13.1% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $93.48 | 11.4% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $78.71 | 9.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.53 | 7.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.57 | 7.2% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $42.63 | 5.2% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $30.81 | 3.8% | 1 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $23.04 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $817.91 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Itovebi Normalized: itovebi |
Biological | Genentech, Inc. | $132.13 | 1 | 2025 |
Source payment records
|
|||||
| EMRELIS Normalized: emrelis |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $93.48 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $62.59 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $58.57 | 2 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $42.83 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $42.83 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $42.63 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $38.99 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $35.88 | 1 | 2025 |
Source payment records
|
|||||
| FLUENT FLUID MANAGEMENT SYSTEM Normalized: fluent fluid management system |
Device | Hologic Sales and Service, LLC | $30.81 | 1 | 2025 |
Source payment records
|
|||||
| MYOSURE TISSUE REMOVAL DEVICE Normalized: myosure tissue removal device |
Device | Hologic Sales and Service, LLC | $30.81 | 1 | 2025 |
Source payment records
|
|||||
| NOVASURE Normalized: novasure |
Device | Hologic Sales and Service, LLC | $30.81 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $28.92 | 1 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $24.54 | 1 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $23.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| IMBRUVICA imbruvica |
2025 | Imbruvica | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 17 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | VERZENIO open payments reported associated product |
CMS Open Payments — General Payments 9278 supporting records · 4763 recipient NPIs · example record 1186464449 |
Verzenio · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 400 | 91 |
| Hydroxyurea | Hydroxyurea | 110 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 106 | 52 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 97 | 51 |
| Potassium Chloride | Potassium Chloride | 95 | 22 |
| Gabapentin | Gabapentin | 78 | 17 |
| Prednisone | Prednisone | 75 | 19 |
| Abiraterone Acetate | Abiraterone Acetate | 74 | suppressed |
| Eliquis | Apixaban | 66 | 17 |
| Acyclovir | Acyclovir | 63 | 11 |
| Imbruvica | Ibrutinib | 57 | suppressed |
| Dexamethasone | Dexamethasone | 52 | 26 |
| Xtandi | Enzalutamide | 50 | suppressed |
| Letrozole | Letrozole | 49 | 11 |
| Exemestane | Exemestane | 48 | suppressed |
| Lenalidomide | Lenalidomide | 45 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 40 | 12 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 40 | 34 |
| Raloxifene Hcl | Raloxifene Hcl | 39 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | 14 |
| Calquence | Acalabrutinib Maleate | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 16 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Brukinsa | Zanubrutinib | 14 | suppressed |
| Furosemide | Furosemide | 14 | suppressed |
| Kisqali | Ribociclib Succinate | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Verzenio | Abemaciclib | 14 | suppressed |
| Zykadia | Ceritinib | 14 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 13 | suppressed |
| Promacta | Eltrombopag Olamine | 13 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Tagrisso | Osimertinib Mesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $817.91 · 16 records | ABBVIE INC. | DARZALEX, ELREXFIO, EMRELIS, EPKINLY, ERLEADA, FLUENT FLUID MANAGEMENT SYSTEM, IMBRUVICA, Itovebi, MYOSURE TISSUE REMOVAL DEVICE, NOVASURE, Orserdu, REBLOZYL, TECVAYLI, TRELEGY ELLIPTA, XT CDX, XTANDI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Imbruvica play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error